Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Stock analysts at HC Wainwright dropped their Q3 2025 earnings per share estimates for shares of Mind Medicine (MindMed) in a research report issued to clients and investors on Wednesday, May 21st. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.36) for the quarter, down from their previous estimate of ($0.35). HC Wainwright currently has a "Buy" rating and a $55.00 target price on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share. HC Wainwright also issued estimates for Mind Medicine (MindMed)'s FY2025 earnings at ($1.32) EPS and FY2027 earnings at ($1.31) EPS.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.01.
Several other equities research analysts have also weighed in on the company. Cantor Fitzgerald raised Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Tuesday, May 13th. Robert W. Baird cut their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, March 7th. Evercore ISI began coverage on Mind Medicine (MindMed) in a research report on Tuesday, January 28th. They set an "outperform" rating and a $23.00 target price on the stock. Finally, Chardan Capital reissued a "buy" rating and set a $20.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, May 9th. Nine research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Mind Medicine (MindMed) has a consensus rating of "Buy" and an average price target of $25.11.
Get Our Latest Stock Report on Mind Medicine (MindMed)
Mind Medicine (MindMed) Stock Up 0.1%
Shares of MNMD traded up $0.01 during midday trading on Monday, hitting $7.15. The company had a trading volume of 869,260 shares, compared to its average volume of 1,392,730. The company's 50-day simple moving average is $6.22 and its 200-day simple moving average is $6.97. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.00 and a current ratio of 9.00. The firm has a market capitalization of $538.88 million, a P/E ratio of -3.16 and a beta of 2.52. Mind Medicine has a 1 year low of $4.70 and a 1 year high of $10.44.
Insiders Place Their Bets
In other Mind Medicine (MindMed) news, insider Daniel Karlin sold 6,836 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $46,074.64. Following the transaction, the insider now owns 446,177 shares of the company's stock, valued at $3,007,232.98. The trade was a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Robert Barrow sold 21,208 shares of Mind Medicine (MindMed) stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $142,941.92. Following the transaction, the chief executive officer now directly owns 856,556 shares in the company, valued at approximately $5,773,187.44. This trade represents a 2.42% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,391 shares of company stock valued at $204,835 over the last quarter. Company insiders own 2.45% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Diadema Partners LP purchased a new position in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $33,000. Hollencrest Capital Management grew its stake in shares of Mind Medicine (MindMed) by 10,833.3% in the 4th quarter. Hollencrest Capital Management now owns 7,216 shares of the company's stock valued at $50,000 after purchasing an additional 7,150 shares during the last quarter. Black Swift Group LLC purchased a new position in shares of Mind Medicine (MindMed) in the 1st quarter valued at approximately $63,000. CreativeOne Wealth LLC purchased a new position in shares of Mind Medicine (MindMed) in the 1st quarter valued at approximately $67,000. Finally, King Wealth Management Group purchased a new position in shares of Mind Medicine (MindMed) in the 4th quarter valued at approximately $70,000. Institutional investors and hedge funds own 27.91% of the company's stock.
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Further Reading

Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.